The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.
Pancreatic Cancer Early Detection
Clinicaltrials.gov identifier:
NCT02206360
Prevention
Study Contact Information:
Lisa Schuldt, BSN
914-849-7582
lschuldt@wphospital.org
Pancreatic Cancer Early Detection Program
About the Study
This is a study looking at esophageal as a screening for pancreatic cancer in high risk individuals. The study will enroll people with an inherited risk for cancer due to a or CDKN2A mutation with or without a family history of pancreatic cancer. The study will also enroll people with a first- or second-degree relative with pancreatic cancer with (, , , , ) or any of the following mutations , P53, , APC, or .
What the Study Entails
Enrolled subjects will undergo Endoscopic (EUS) alternating with Magnetic Resonance Imaging (), every six to 12 months, for up to 5 years.
Study Site
White Plains, NY
White Plains Hospital
Lisa Schuldt, BSN by phone: 914-849-7582 or email lschuldt@wphospital.org
Study Lead Investigator
Principal Investigator: Joshua P Raff, MD
People at elevated risk for pancreatic cancer
- Known carrier of either the
or CDKN2A mutation - Known carrier of any of the following mutations (
,,,,,,P53,,APC, or) PLUS first- or second-degree relative affected with pancreatic cancer; - Individual with Peutz-Jeghers Syndrome;
- Familial Pancreatic Cancer, defined as at least two affected relatives with Pancreatic Cancer, who are with each other, and at least one of those affected must be first degree relative to the study subject;
- Both parents affected, any age:
- Any first degree relative diagnosed with pancreatic cancer under age 50;
- Chronic Pancreatitis Syndrome, defined by either PRSS1 or SPINK1 mutations AND appropriate clinical and family history
Patients are excluded if they have:
- any medical condition that contraindicates endoscopy or biopsy
- any medical condition that contraindicates
- history of pancreatic cancer, either endocrine or exocrine
- clinical suspicion of pancreatic cancer, or any previous radiographic or histologic diagnosis of a pre-malignant finding, including IPMN (Intraductal papillary mucinous neoplasm) and PanIN (Pancreatic intraepithelial Neoplasm).
- diagnosis of dementia
- uncontrolled, current illness
- renal insufficiency with serum creatinine greater than 2.0 mg/dl